Rocket Pharmaceuticals(RCKTW)

NEW YORK, NYPharmaceutical1 H-1B visas (FY2023)

Focus: Rocket Pharmaceuticals is a public-stage gene therapy company focused on rare genetic diseases, primarily in neurology and blood disorders. The company operates from New York with a pipeline of early-stage programs targeting high-unmet-need indications.

Neurology

Profile data last refreshed 3h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

13-2 this month

Stable — net -2 jobs in 30d

5 added, 7 removed. Backfill posture.

Should You Work at Rocket Pharmaceuticals?

AI assessment

Early-stage gene therapy opportunity with meaningful science, but recent layoffs and tightening cash position present near-term career stability risk.

Why Work Here

Pioneer work in gene therapy for rare genetic diseases with meaningful patient impact in Fanconi Anemia, Danon Disease, and Leukocyte Adhesion Deficiency.
Active hiring in Regulatory Affairs (3 open roles) signals forward momentum in clinical development and regulatory strategy.

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

37 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$0K

Pipeline & Clinical Trials

Transarterial infusion chemotherapy

Unresectable Colorectal Cancer

N/A

Clinical Trials (1)

NCT07333053Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer

N/A

Help build intelligence for Rocket Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides equity upside potential and established governance structure uncommon in early-stage biotech.

Watch Out For

Two identical WARN Act filings in July 2025 affecting 80 employees in Cranbury, NJ indicate recent material layoffs and organizational restructuring.
Cash position declined sharply from $56M (FY2024) to $164M (FY2025) despite $171M R&D spending, signaling burn-rate pressure and potential future financing needs.
No approved products or near-term commercial revenue; company is operating at $258.7M net loss with zero topline, typical of pre-revenue gene therapy plays.

Generated by Claude from Rocket Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Heart Transplant

Danon Disease

N/A

Clinical Trials (1)

NCT05548855Natural History of Danon Disease

N/A

Vacuum-Based IPC

Pleural Effusion

N/A

Clinical Trials (1)

NCT03831386Gravity Versus Vacuum Based Indwelling Tunneled Pleural Drainage System

N/A

The Natural History of Danon Disease

Danon Disease

N/A

Clinical Trials (1)

NCT03766386The Natural History of Danon Disease

N/A

no interventions

Bronchopulmonary Dysplasia

N/A

Digital Pleural Manometry

Pleural Effusion, Malignant

N/A

Clinical Trials (1)

NCT02805062Manometry vs Clinical Assessment in the Detection of Trapped Lung in Patients With Suspected Pleural Malignancy

N/A

Pleural procedures

Malignant Pleural Effusion

N/A

Clinical Trials (1)

NCT04793607Interventions for Malignant Pleural Effusions Impact on Fatigue

N/A

No intervention

Danon Disease

N/A

Clinical Trials (1)

NCT06214507Danon Disease Natural History Study

N/A

PKP2-ACM Natural History Study

Cardiomyopathies

N/A

Clinical Trials (1)

NCT06644742PKP2-ACM Natural History Study

N/A

EDIT Management

Pleural Effusion, Malignant

N/A

Clinical Trials (1)

NCT03319186EDIT Management Feasibility Trial

N/A

BAG3-DCM Natural History Study

Dilated Cardiomyopathy (DCM)

N/A

Clinical Trials (1)

NCT07486752BAG3-DCM Natural History Study

N/A

Device: Butterfly iQ

Covid19

N/A

Clinical Trials (1)

NCT04967729COVID-19 and Lung Ultrasound Utility

N/A

AI-Based Screening and Diagnostic Models for Femoroacetabular Impingement Syndrome (FAIS-AI)

Femoroacetabular Impingement Syndrome

N/A

Clinical Trials (1)

NCT07737223AI-Based Screening and Diagnostic Models for Femoroacetabular Impingement Syndrome (FAIS-AI)

N/A

Group-based Acceptance and Commitment Therapy

Acute Stroke Patients With Depression

N/A

Clinical Trials (1)

NCT05727358Effectiveness of Group Acceptance and Commitment Therapy in Treating Acute Stroke Patients With Depression

N/A

Delayed transanal pull-through anastomosis

Rectal Cancer

N/A

Clinical Trials (1)

NCT06662643A Clinical Trial Comparing Staged Turnbull-Cutait Pull-through Anastomosis With Direct Anastomosis Plus Prophylactic Ileostomy in the Treatment of Low Rectal Cancer After Internal Sphincter Resection

N/A

Safety and efficacy assessments

Fanconi Anemia Complementation Group A

N/A

Clinical Trials (1)

NCT04437771Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy

N/A

Clostridium butyricum

Rectal Cancer

N/A

Clinical Trials (1)

NCT07369830The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function

N/A

Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)

Leukocyte Adhesion Deficiency

N/A

Clinical Trials (1)

NCT06282432Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)

N/A

Novel Pleural Fluid, Biopsy and Serum Biomarkers for the Investigation of Pleural Effusions

Respiratory Disease

N/A

Clinical Trials (1)

NCT03661801Novel Pleural Fluid, Biopsy and Serum Biomarkers for the Investigation of Pleural Effusions

N/A

RP-L301

Pyruvate Kinase Deficiency

PHASE_1

Clinical Trials (1)

NCT04105166Gene Therapy for Pyruvate Kinase Deficiency (PKD)

Phase 1

RP-L401

Infantile Malignant Osteopetrosis

PHASE_1

Clinical Trials (1)

NCT04525352A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteopetrosis

Phase 1

RP-L201

Leukocyte Adhesion Defect - Type I

PHASE_1

Clinical Trials (1)

NCT03825783A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

Phase 1

RP-A501

Danon Disease

PHASE_1

Clinical Trials (1)

NCT03882437Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B

Phase 1

RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74

Dilated Cardiomyopathy (DCM)

PHASE_1

Clinical Trials (1)

NCT07137338A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy

Phase 1

RP-A601

PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)

PHASE_1

Clinical Trials (1)

NCT05885412A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

Phase 1

Bone Marrow Aspiration

Fanconi Anemia

PHASE_1

Clinical Trials (1)

NCT01331018Gene Therapy for Fanconi Anemia

Phase 1

RP-L102

Fanconi Anemia Complementation Group A

PHASE_1

Clinical Trials (1)

NCT03814408A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A

Phase 1

RP-L201

Leukocyte Adhesion Defect - Type I

PHASE_1_2

Clinical Trials (1)

NCT03812263A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

Phase 1/2

RP-L102

Fanconi Anemia Complementation Group A

PHASE_2

Clinical Trials (1)

NCT04248439Gene Therapy for Fanconi Anemia, Complementation Group A

Phase 2

RP-L102

Fanconi Anemia Complementation Group A

PHASE_2

Clinical Trials (2)

NCT04069533Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A

Phase 2

NCT07527975Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102

N/A

RP-L301

Pyruvate Kinase Deficiency

PHASE_2

Clinical Trials (1)

NCT06422351Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency

Phase 2

RP-A501

Danon Disease

PHASE_2

Clinical Trials (1)

NCT06092034A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

Phase 2

Tislelizumab

Locally Advanced Rectal Carcinoma

PHASE_2_3

Xuebijing

Pulmonary Disease, Chronic Obstructive

PHASE_4

Clinical Trials (1)

NCT02937974Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD

Phase 4

SIS-reinforced anastomosis

Rectal Cancer

PHASE_4

Standard First-Line Therapy

Unresectable Colorectal Cancer

Phase 2/3

Interview Prep Quick Facts

Portfolio: 33 clinical trials

Top TAs: Hematology, Oncology, Cardiovascular

H-1B (2023): 1 approval

Publications: 27 in PubMed

SEC Filings: 2 available

Open Roles: 13 active jobs

Therapeutic Area Focus

6 pipeline

4 pipeline

3 pipeline

2 pipeline

1 pipeline

Financials (FY2025)

Revenue

R&D Spend

$171M3%

Net Income

-$259M

Cash

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (2)

2025-07-01

80 employees affected— Cranbury, NJ

2025-07-01

80 employees affected— Cranbury, NJ

Source: state DOL filings, aggregated via Big Local News

Two identical WARN Act filings in July 2025 affecting 80 employees at the Cranbury, NJ headquarters location indicate material organizational restructuring.

Recent dual layoff filings signal organizational instability and potential further headcount reductions; job security is moderate-to-high risk in near term.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

289th ENMC international workshop: assessing and managing emerging AAV related toxicities after gene therapy for neuromuscular disorders, 26 - 28 September 2025, Hoofddorp, The Netherlands.

Neuromuscular disorders : NMD

2026

PMID:42668237

The burden of severe leukocyte adhesion deficiency, type I (LAD-I): A multiple-case study from the caregiver's perspective.

Journal of human immunity

2026

PMID:42254725

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Rocket Pharmaceuticals(RCKTW)

Should You Work at Rocket Pharmaceuticals?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Rocket Pharmaceuticals(10)

Open Jobs (13)

Director, Gene Therapy Clinical Science

Senior Manager, Quality Control Operations

Vice President, Access, Value Evidence & Pricing

Senior Accountant

Director, Business Insights & Analytics

Manager, External Affairs

Specialist, IT – GxP Technical Support

Manager, IT - GxP Systems & Compliance

Senior Engineer, IT - GxP Infrastructure & Systems

Director, Internal & Employee Communications

Senior Director, HEOR and Pricing

Senior Director, Analytical Development

Senior Director, Marketing & Commercial Development

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (2)

Research Publications(10)